Patent details
300849
Product Name:
everolimus, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
The time of generation of the report may vary depending on the number of the selected files and the pages of each file. If the generation of the consolidated PDF file takes long, you may reduce the number of selected files and proceed with the generation of the PDF in batches.
Ok
Cancel
You have not selected any documents
Ok
Basic Information
Publication number:
300849
Type:
Certificate
SPC Type:
Medical
Basic Patent Number:
EP2269604
Status:
Withdrawn
Application number:
300849
Procedural language:
Dutch
First Applicant Residence Country:
Switzerland (CH)
Marketing Authorization
Marketing Authorization Number:
EU/1/09/538/001-006 (C(2009)6251)
Marketing Authorization Type:
EEA
Marketing Authorization Date:
05/08/2009
Marketing Authorization Country:
European Union (EU)
Dates
Filing date:
15/12/2016
First Marketing Authorization date:
05/08/2009
Grant date:
Activation date:
Lapsed By Non Payment Annual Fee Date:
Renunciation Date:
NullificationDate:
Registration date:
19/12/2016
SPC/SPC Extension Expiration Date:
Lapsed By Expiration Date:
Withdrawal date:
22/10/2020
Revocation Date:
Invalidity Date:
Withdrawal Market Authorization Date:
Refusal Date:
Applicant/holder
From:
09/09/2020
Name:
Novartis Pharma AG
Address:
Lichtstrasse 35, 4056, Basel, Switzerland (CH)
Historical Applicant/holder
From:
26/09/2018
To:
09/09/2020
Name:
Novartis Pharma AG
Address:
Lichtstrasse 35, 4056, Basel, Switzerland (CH)
From:
26/09/2018
To:
09/09/2020
Name:
Novartis International Pharmaceutical AG
Address:
Lichtstrasse 35, 4056, Basel , Switzerland (CH)
From:
20/12/2016
To:
26/09/2018
Name:
Novartis AG
Address:
Lichtstrasse 35, 4002, Basel, Switzerland (CH)
Agent
Name:
ir. M.F.J.M. Ketelaars c.s.
From:
19/12/2016
Address:
NLO
Postbus 29720, 2502 LS, Den Haag, Netherlands (NL)
To:
Licensee
Name:
Novartis Pharma B.V.
From:
10/05/2019
Address:
Raapopseweg 1, 6824 DP, Arnhem, Netherlands (NL)
To:
Publication
Bulletin
1
Bulletin Heading:
VRV
Journal edition number:
44/20
Publication date:
28/10/2020
Description:
Lapse or annulment
2
Bulletin Heading:
CO
Journal edition number:
39/20
Publication date:
23/09/2020
Description:
Changes in the Netherlands Patent Register
3
Bulletin Heading:
MED
Journal edition number:
25/19
Publication date:
19/06/2019
Description:
Other communications
4
Bulletin Heading:
CO
Journal edition number:
49/18
Publication date:
28/11/2018
Description:
Changes in the Netherlands Patent Register
5
Bulletin Heading:
SPC
Journal edition number:
51/16
Publication date:
21/12/2016
Description:
Applications and granted Supplementary Protection Certificates (or the extensions of the Supplementary Protection Certificates)
Deed
Change of owner(s)
Change Kind/ Decision Type:
Merge
Deed Number:
RC202001757A
Date Registered:
09/09/2020
License Effective Date:
License Expiration Date:
Scope of License:
Deed Filer:
ir. M.F.J.M. Ketelaars c.s.
Journal Edition Number:
Text:
Deed Status:
Country Code:
Updated License Number:
Terminated License Number:
Added Owner(s)
1
Name:
Novartis Pharma AG
Address:
Lichtstrasse 35, 4056, Basel, Switzerland (CH)
2
Name:
Novartis Pharma AG
Address:
Lichtstrasse 35, 4056 BASEL, Switzerland (CH)
Changed Pledgee
Name:
Address:
Removed Usufructuary
Name:
Address:
Added Usufructuary
Name:
Address:
Changed Usufructuary
Name:
Address:
Licence
Change Kind/ Decision Type:
New licence registration
Deed Number:
RC201900908A
Date Registered:
10/05/2019
License Effective Date:
10/05/2018
License Expiration Date:
Scope of License:
Not Exclusive
Deed Filer:
ir. M.F.J.M. Ketelaars c.s.
Journal Edition Number:
Text:
Deed Status:
Country Code:
Netherlands (NL)
Updated License Number:
Terminated License Number:
Added Licensee(s)
Name:
Novartis Pharma B.V.
Address:
Raapopseweg 1, 6824 DP, Arnhem, Netherlands (NL)
Changed Pledgee
Name:
Address:
Removed Usufructuary
Name:
Address:
Added Usufructuary
Name:
Address:
Changed Usufructuary
Name:
Address:
Change of owner(s)
Change Kind/ Decision Type:
Assignment
Deed Number:
RC201801726A
Date Registered:
26/09/2018
License Effective Date:
License Expiration Date:
Scope of License:
Deed Filer:
ir. M.F.J.M. Ketelaars c.s.
Journal Edition Number:
Text:
Deed Status:
Country Code:
Updated License Number:
Terminated License Number:
Added Owner(s)
1
Name:
Novartis Pharma AG
Address:
Lichtstrasse 35, 4056, Basel, Switzerland (CH)
2
Name:
Novartis International Pharmaceutical AG
Address:
Lichtstrasse 35, 4056, Basel , Switzerland (CH)
Changed Pledgee
Name:
Address:
Removed Usufructuary
Name:
Address:
Added Usufructuary
Name:
Address:
Changed Usufructuary
Name:
Address:
Filing date
Document type
Document Description
Number of pages
File Type
26/10/2020
Outgoing Correspondence
Letter confirmation withdrawal
1
PDF
/2/5/3/6/1/0800116352/docs/300849_3_374616l193.pdf
22/10/2020
SPC Documents
Accompanying letter SPC
1
PDF
/2/5/3/6/1/0800116352/docs/300849_0_supplprotectioncertificate20201023105148036.pdf
23/07/2020
Outgoing Correspondence
Letter to applicant
3
PDF
/2/5/3/6/1/0800116352/docs/300849_4_354239l173.pdf
20/12/2016
Outgoing Correspondence
Confirmation receipt request
1
PDF
/2/5/3/6/1/0800116352/docs/300849_8_104297l174.pdf
15/12/2016
SPC Documents
Annex SPC
10
PDF
/2/5/3/6/1/0800116352/docs/300849_1_supplprotectioncertificate20200421012813392.pdf
15/12/2016
SPC Documents
Annex SPC
1
PDF
/2/5/3/6/1/0800116352/docs/300849_2_supplprotectioncertificate20200421012249531.pdf
15/12/2016
SPC Documents
Accompanying letter SPC
4
PDF
/2/5/3/6/1/0800116352/docs/300849_5_supplprotectioncertificate20210406024527747.pdf
15/12/2016
SPC Documents
Marketing Authorization SPC
5
PDF
/2/5/3/6/1/0800116352/docs/300849_6_supplprotectioncertificate20161219041609878.pdf
15/12/2016
SPC Documents
Summary of the characteristics of the product
27
PDF
/2/5/3/6/1/0800116352/docs/300849_7_supplprotectioncertificate20161219041609993.pdf
15/12/2016
Application Form
First filed application form
2
PDF
/2/5/3/6/1/0800116352/docs/300849_9_applicationform20161219041609605.pdf